Last updated: 21 July 2019 at 9:58pm EST

Ventures, Inc. Med Immune Net Worth




The estimated Net Worth of Ventures, Inc. Med Immune is at least $16.4 Million dollars as of 15 December 2017. Ventures Immune owns over 200,000 units of Cortexyme Inc stock worth over $5,753,729 and over the last 20 years Ventures sold CRTX stock worth over $10,596,644.

Ventures Immune CRTX stock SEC Form 4 insiders trading

Ventures has made over 7 trades of the Cortexyme Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Ventures sold 200,000 units of CRTX stock worth $3,950,000 on 15 December 2017.

The largest trade Ventures's ever made was buying 223,439 units of Cortexyme Inc stock on 30 June 2015 worth over $2,681,268. On average, Ventures trades about 141,440 units every 169 days since 2004. As of 15 December 2017 Ventures still owns at least 2,950,630 units of Cortexyme Inc stock.

You can see the complete history of Ventures Immune stock trades at the bottom of the page.



What's Ventures Immune's mailing address?

Ventures's mailing address filed with the SEC is 79 T W Alexander Drive #4501 Ste 100, Research Triangle Park, NC 27709, United States.

Insiders trading at Cortexyme Inc

Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.



What does Cortexyme Inc do?

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.



What does Cortexyme Inc's logo look like?

Cortexyme Inc logo

Complete history of Ventures Immune stock trades at Applied Genetic Technologies Corp, Astria Therapeutics Inc, G1 Therapeutics Inc, and Cortexyme Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Dec 2017 Ventures, Inc. Med Immune
10% owner
Sale 200,000 $19.75 $3,950,000
15 Dec 2017
2,950,630
1 Dec 2017 Ventures, Inc. Med Immune
10% owner
Sale 133,906 $19.75 $2,644,644
1 Dec 2017
3,150,630
20 Nov 2017 Ventures, Inc. Med Immune
10% owner
Sale 200,000 $20.01 $4,002,000
20 Nov 2017
3,284,536
22 May 2017 Ventures, Inc. Med Immune
10% owner
Buy 75,000 $15.00 $1,125,000
22 May 2017
3,484,536
30 Jun 2015 Ventures, Inc. Med Immune
10% owner
Buy 223,439 $12.00 $2,681,268
30 Jun 2015
1,632,652
30 Jun 2015 Ventures, Inc. Med Immune
10% owner
Buy 223,439 $12.00 $2,681,268
30 Jun 2015
1,632,652
1 Apr 2014 Ventures, Inc. Med Immune
10% owner
Buy 75,735 $12.00 $908,820
1 Apr 2014
1,452,196


Cortexyme Inc executives and stock owners

Cortexyme Inc executives and other stock owners filed with the SEC include: